C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 495/04 (2006.01) A61K 31/519 (2006.01) A61K 31/5377 (2006.01) A61P 9/12 (2006.01) A61P 11/06 (2006.01) A61P 25/06 (2006.01) A61P 29/00 (2006.01) A61P 31/12 (2006.01) A61P 35/02 (2006.01) A61P 37/02 (2006.01) A61P 37/06 (2006.01) C07D 487/04 (2006.01)
Patent
CA 2703600
The present invention relates to N-containing heterocyclic compounds that are inhibitors of protein kinases including JAK kinases. In particular, the compounds are selective for JAK1, JAK2, JAK3 or TYK2 kinases and combinations thereof such as JAK1 and JAK2. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases; and vascular diseases.
La présente invention concerne des composés hétérocycliques à teneur en N qui sont des inhibiteurs de protéines kinases y compris des kinases JAK. En particulier, les composés sont sélectifs pour les kinases JAK1, JAK2, JAK3 ou TYK2 et leurs combinaisons, telles que JAK1 et JAK2. Les inhibiteurs de kinases peuvent être utilisés dans le traitement de maladies associées aux kinases, telles que les maladies immunologiques et inflammatoires comprenant les transplantations d'organe ; les maladies hyperprolifératives comprenant le cancer et le syndrome myéloprolifératif ; les maladies virales ; les maladies métaboliques et les maladies vasculaires.
Bourke David Gerard
Burns Christopher John
Cuzzupe Anthony Nicholas
Feutrill John Thomas
Kling Marcel Robert
Norton Rose Or S.e.n.c.r.l. S.r.l./llp
Ym Biosciences Australia Pty Ltd
LandOfFree
N-containing heterocyclic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N-containing heterocyclic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-containing heterocyclic compounds will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1427541